Core Viewpoint - UBS maintains a "Buy" rating for Hengan International (01044), raising profit forecasts for 2026 to 2028 by 4% to 9% due to strong performance in the second half of last year and better-than-expected results in high-end products [1] Group 1: Financial Performance - Hengan's revenue for the second half of 2025 is expected to grow by 3.9% to 11 billion RMB, with net profit rising by 31% to 1.1 billion RMB, outperforming both UBS and market expectations [1] - Excluding foreign exchange impacts, net profit is estimated to grow by 21% year-on-year in the second half [1] - The overall gross margin improved by 4 percentage points year-on-year and 3 percentage points quarter-on-quarter to 35.5%, benefiting from lower raw material prices and increased sales of high-margin products [1] Group 2: Business Highlights - Sales of tissue and hygiene products increased by 8% year-on-year in the second half, accelerating from 3% growth in the first half [1] - The management indicated a 5% growth in tissue product sales for 2025, supported by an improved high-end product mix and a 1 percentage point increase in average price [1] - Although sales of hygiene products declined, this was offset by an increase in average prices [1] Group 3: Industry Outlook - The management expects continued intense competition in the hygiene products industry in 2026, planning to shift towards mid-to-high-end products to avoid price wars [2] - While wood pulp prices are expected to stabilize, there are concerns about supply chain uncertainties and raw material price increases due to conflicts in the Middle East [2] - Expansion into international markets and new product categories is anticipated to be the two main drivers of sales growth over the next five years [2] - Major shareholders may continue to increase their holdings, reflecting confidence in the company's prospects [2]

Core Viewpoint - UBS report indicates that Hengan International's revenue for the second half of 2025 is expected to grow by 3.9% year-on-year to 11 billion yuan, with net profit rising by 31% year-on-year to 1.1 billion yuan, outperforming both UBS and market expectations [1] Financial Performance - Excluding foreign exchange gains and losses, net profit for the second half is estimated to grow by 21% year-on-year [1] - The tissue and hygiene products segment is projected to see sales growth of 8% year-on-year in the second half, accelerating from 3% growth in the first half [1] - The decline in sales volume for hygiene products is offset by an increase in average selling prices [1] - Overall gross margin is expected to improve by 4 percentage points year-on-year and 3 percentage points quarter-on-quarter to 35.5%, benefiting from lower raw material prices and increased sales of high-margin products [1] Earnings Forecast and Target Price - Considering Hengan's strong performance in the second half of last year and better-than-expected results from high-end products, UBS has raised its earnings forecasts for Hengan International for 2026 to 2028 by 4% to 9% [1] - The target price has been adjusted from 32.5 HKD to 34.9 HKD, equivalent to a projected price-to-earnings ratio of 14 times for 2026, while maintaining a "Buy" rating [1]

Core Viewpoint - Citigroup has slightly adjusted its profit forecast for Hengan International (01044) for 2026 and 2027, increasing the target price from HKD 27 to HKD 28.2 while maintaining a "Neutral" rating [1] Group 1: Financial Performance - Hengan's net profit for the second half of 2025 is expected to rebound by 31% year-on-year, driven by a recovery in gross margin from a low base, aligning with Citigroup's expectations [1] - Revenue growth for the second half of 2025 is projected at 4%, meeting forecasts, with improved sales in tissue and hygiene products offsetting declines in other business segments [1] - The gross margin across all business segments in the second half of 2025 is anticipated to exceed expectations, although this is countered by lower government subsidies and higher advertising and promotional expenses, resulting in operating profit and net profit meeting projections [1] Group 2: Management Outlook - Despite the stable performance in the second half of 2025, management aims to maintain stable sales and profit margins in 2026 due to intense competition and potential pressure from raw material costs [1] - Management plans to address potential challenges by improving product mix and enhancing operational efficiency [1]

Core Viewpoint - Citigroup has adjusted its profit forecasts for Hengan International (01044) for 2026 and 2027, increasing the target price from HKD 27 to HKD 28.2 while maintaining a "Neutral" rating [1] Group 1: Financial Performance - Hengan's net profit for the second half of 2025 is expected to rebound by 31% year-on-year, driven by a recovery in gross margin from a low base, aligning with Citigroup's expectations [1] - Revenue growth for the second half of 2025 is projected at 4%, meeting forecasts, with improved sales in tissue and hygiene products offsetting declines in other business segments [1] - Gross margins across all business segments in the second half of 2025 are stronger than expected, although lower government subsidies and higher advertising and promotional expenses have offset this, resulting in operating profit and net profit meeting expectations [1] Group 2: Management Outlook - Despite the stable performance in the second half of 2025, management aims to maintain stable sales and profit margins in 2026 due to intense competition and potential pressure from raw material costs [1] - Management plans to address potential challenges by improving product mix and enhancing operational efficiency [1]

Core Viewpoint - Citigroup's report indicates that Hengan International's net profit is expected to rebound by 31% year-on-year in the second half of 2025, driven by a recovery in gross margin from a low base, aligning with the bank's expectations [1] Financial Performance - Revenue is projected to grow by 4%, meeting forecasts, with improvements in tissue and hygiene product sales offsetting declines in other business segments [1] - Gross margins across all business segments exceeded expectations, although lower government subsidies and higher advertising and promotional expenses offset this, resulting in operating profit and net profit meeting projections [1] Management Outlook - Despite the stable performance in the second half of 2025, management aims to maintain stable sales and profit margins in 2026 due to intense competition and potential pressure from raw material costs [1] - Management plans to address potential challenges by improving product mix and enhancing operational efficiency [1] Forecast Adjustments - Citigroup has slightly adjusted its net profit forecasts for Hengan for 2026 and 2027 by approximately 1% [1] - The target price based on the sum-of-the-parts valuation method has been raised from HKD 27 to HKD 28.2, while maintaining a "Neutral" rating [1]

Group 1 - The stock of Hengan International (01044.HK) saw an increase of over 4% in the afternoon trading session on March 17, with a current rise of 2.97%, priced at HKD 28.42 [1] - The trading volume reached HKD 41.433 million [1]

Core Viewpoint - Hengan International (01044) reported a revenue increase of 1.8% year-on-year for the fiscal year ending December 31, 2025, driven by growth in tissue sales, despite a decline in hygiene product sales and increased promotional expenses [1] Financial Performance - The company achieved a total revenue of 23.069 billion RMB for the fiscal year, with a profit attributable to equity holders of 2.535 billion RMB, reflecting a year-on-year increase of 10.3% [1] - The overall gross profit for 2025 rose approximately 6.6% to around 7.806 billion RMB, supported by effective tissue sales growth [1] Dividend Announcement - Hengan International proposed a final dividend of 0.7 RMB per share [1] Margin Improvement - The gross margin improved to approximately 33.8% for the year, attributed to reduced promotional spending on tissue products and a recovery in hygiene product sales in the second half of 2025 [1]

Group 1 - The core viewpoint of the article highlights that Hengan International (01044) has shown a positive performance in its stock price, with an increase of 2.97% to HKD 28.42, and a trading volume of HKD 41.43 million [1] - For the fiscal year ending December 31, 2025, Hengan International reported a revenue of RMB 23.069 billion, reflecting a year-on-year increase of 1.8% [1] - The profit attributable to equity holders reached RMB 2.535 billion, which is a 10.3% increase compared to the previous year [1] Group 2 - The sales growth of tissue products effectively offset the decline in sales of hygiene products and the increase in promotional expenses, leading to an overall gross profit increase of approximately 6.6% to around RMB 7.806 billion for 2025 [1] - In the second half of 2025, a reduction in tissue promotions and a recovery in hygiene product sales contributed to an improvement in the overall gross margin to approximately 33.8% [1] - The company proposed a final dividend of RMB 0.7 per share [1]

Group 1 - The company, Hengan International (01044.HK), reported a revenue of 23.069 billion RMB for the year ending December 31, 2025, representing a year-on-year increase of 1.8% [1] - The profit attributable to equity holders of the company was 2.535 billion RMB, which is a year-on-year increase of 10.3% [1] - The basic earnings per share were reported at 2.227 RMB, and the company proposed a final dividend of 0.7 RMB per share [1]

Group 1 - The company, Hengan International (01044.HK), announced a final dividend of RMB 0.7 per share to be distributed on June 5, 2026 [1] - The stock has low attention from investment banks, with no ratings provided in the last 90 days [2] - Hengan International has a market capitalization of HKD 32.619 billion and ranks second in the paper manufacturing industry [2]